Treatment of Helicobacter pylori infection: Where are we now?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 12, 2016, Pages 1918-1926

  Liou, Jyh Ming ^a   Wu, Ming Shiang ^a,b   Lin, Jaw Town ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Asia; eradication; gastric cancer; Helicobacter pylori; resistance

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASIA; BACTERIAL CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; META ANALYSIS (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES BOULARDII; STOMACH CANCER; TREATMENT DURATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ASIA; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; PROBIOTICS; PROTON PUMP INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84997107059     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13418     Document Type: Review

References (52)

1. World Health Organization Internal Association of Cancer Registries. 2012 http://globocan.iarc.fr/Pages/age-specific_table_sel.aspx [Accessed 02 July 2012].
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N. Engl. J. Med. 2002; 347: 1175–86.
3. Malfertheiner P, Megraud F, O'Morain CA et al. Management of helicobacter pylori infection - the Maastricht IV/ Florence consensus report. Gut 2012; 61: 646–64.
4. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007; 102: 1808–25.
5. Miwa H, Go MF, Sato N. H. pylori and gastric cancer: the Asian enigma. Am. J. Gastroenterol. 2002; 97: 1106–12.
6. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641–8. e1–2.
7. Lee YC, Chen TH, Chiu HM et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013; 62: 676–82.
8. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int. J. Cancer 2013; 132: 1272–6.
9. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008; 5: 321–31.
10. Liou JM, Chen CC, Chang CY et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2015 Sep 3. DOI: 10.1136/gutjnl-2015-310142.
11. Liou JM, Chang CY, Chen MJ et al. The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors-a nationwide study. PLoS One 2015; 10: e0124199.
12. Yuan Y, Ford AC, Khan KJ et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst. Rev. 2013; 12: CD008337.
13. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 79–88.
14. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol. 2006; 101: 488–96.
15. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2008; 28: 868–77.
16. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88: 33–45.
17. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am. J. Gastroenterol. 2010; 105: 65–73.
18. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905–13.
19. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23–34.
20. Greenberg ER, Anderson GL, Morgan DR et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507–14.
21. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
22. Liou JM, Chen CC, Chen MJ et al. Sequential s versus triple therapy in the first line treatment of Helicobacter pylori -a multicenter, open label, randomised trial. Lancet 2013; 381: 205–13.
23. Losurdo G, Leandro G, Principi M et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by 'geographical weighting'. Int. J. Clin. Pract. 2015; 69: 1112–20.
24. Liou JM, Chen CC, Lee YC et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2016; 43: 470–81.
25. Liu KS, Hung IF, Seto WK et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical first-line and second-line treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014; 63: 1410–5.
26. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. 2006; 23: 35–44.
27. Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol. Drug Saf. 2014; 23: 443–55.
28. Wenzhen Y, Kehu Y, Bin M et al. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. Intern. Med. 2009; 48: 2069–76.
29. Romano M, Cuomo A, Gravina AG et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465–70.
30. Liou JM, Lin JT, Chang CY et al. Levofloxacin-based and clarithromycin-based triple therapies in the first line and second line treatments for Helicobacter pylori infection- a randomized comparative trial with cross over design. Gut 2010; 59: 572–8.
31. López-Góngora S, Puig I, Calvet X et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J. Antimicrob. Chemother. 2015; 70: 2447–55.
32. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J. Gastroenterol. 2008; 14: 5385–402.
33. Liou JM, Chang CY, Sheng WH et al. Gyrase A mutations correlates with susceptibility test and treatment outcomes after levofloxacin-based triple therapy for Helicobacter pylori infection. Antimicrob. Agents Chemother. 2011; 55: 1123–9.
34. Delchier JC, Bastuji-Garin S, Lionel Deforges L et al. Triple therapy guided by molecular detection of antibiotic resistances versus standard triple therapy for Helicobacter pylori infection: a randomized trial. Gut 2012; 61 (Suppl 3): A211.
35. Lee HJ, Kim JI, Cheung DY et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J. Infect. Dis. 2013; 208: 1123–30.
36. Zou J, Dong J, Yu XF. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. Helicobacter 2009; 14: 119–27.
37. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther. 2010; 32: 1069–79.
38. Cammarota G, Branca G, Ardito F et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin. Gastroenterol. Hepatol. 2010; 8: 817–20.e3.
39. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65: 870–8.
40. Zhang W, Chen Q, Liang X et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015; 64: 1715–20.
41. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am. J. Gastroenterol. 2009; 104: 21–5.
42. Liou JM, Chen CC, Chang CY et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J. Antimicrob. Chemother. 2013; 68: 450–6.
43. Liou JM, Chen CC, Chen MJ et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J. Antimicrob. Chemother. 2011; 66: 1847–52.
44. Liou JM, Bair MJ, Chen CC et al. Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori: a randomized trial. Am. J. Gastroenterol. 2016; 111: 381–7.
45. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 1997; 39: 5–12.
46. Kuo CH, Hsu PI, Kuo FC et al. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J. Antimicrob. Chemother. 2013; 68: 222–8.
47. Federico A, Nardone G, Gravina AG et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55–61.e1.
48. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev. Gastroenterol. Hepatol. 2014; 8: 21–8.
49. Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter 2016; 21: 85–90.
50. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374–84.
51. Hsu PI, Kao SS, Wu DC et al. A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection. Medicine (Baltimore) 2015; 94: e2104.
52. Di Caro S, Fini L, Daoud Y et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J. Gastroenterol. 2012; 18: 5669–78.